“Grindeks” is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” consists of four subsidiary companies in Latvia, Estonia and Russia, as well as representative offices in 13 countries. “Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics. Currently “Grindeks” produces 25 active pharmaceutical ingredients. Products of the company are exported to 59 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany, the Netherlands, Japan and the U.S. On 8 July, the Annual Report and the Corporate Social Responsibility Report 2013 of JSC “Grindeks” were submitted to “NASDAQ OMX Riga”. JSC “Grindeks” Chairman of the Board Juris Bundulis: “Following the patients' needs and market trends, "Grindeks" has achieved significant results in 2013. The company concluded the year of 2013 with turnover of 118.46 million euros and profit of 13.5 million euros. More information about the company’s activities is accessible in the Annual Report and the Corporate Social Responsibility Report 2013”. The gLAWcal Team LIBEAC project Tuesday, 8 July 2014 (Source: The Wall Street Journal) This news has been realized by gLAWcal—Global Law Initiatives for Sustainable Development in collaboration with the University Institute of European Studies (IUSE) in Turin, Italy and the University of Piemonte Orientale, Novara, Italy which are both beneficiaries of the European Union Research Executive Agency IRSES Project “Liberalism in Between Europe And China” (LIBEAC) coordinated by Aix-Marseille University (CEPERC). This work has been realized in the framework of Workpackages 4, coordinated by University Institute of European Studies (IUSE) in Turin, Italy.